The American Health Council has welcomed Dr. Julie Brahmer, M.D., as ” Best in Medicine” in recognition of her extensive experience in the field of Medicine.
Dr. Brahmer’s academic career began with the study of Philosophy and Chemistry in 1989 at the Creighton University in Omaha, Nebraska. She then went on to pursue her Medical Degree at the University of Nebraska Medical Center, graduating in 1993. Following this, she secured an internship at the University of Utah in Salt Lake City focusing on Internal Medicine where she advanced to serve as the Chief Medical Resident from 1996-1997. After submitting applications to a variety of medical institutions, she accepted a Fellowship position at Johns Hopkins School of Medicine, where she would remain loyal throughout the course of her medical career. Among her many accomplishments, she received her Board Certification in Medical Oncology by the American Board of Internal Medicine.
Dr. Brahmer is currently the Director of the Thoracic Oncology Program and Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center. In addition, she is the co-principal investigator of Johns Hopkins National Clinical Trials Network and is the Director of the Kimmel Cancer Center on the John Hopkins Bayview campus. In the highly prestigious roles that she holds, she specializes in Lung Cancer, Clinical Trials, Mesothelioma, Immunotherapy, as well as the study and treatment of tumors. As Director of the Thoracic Oncology Group and the Co-Director of Johns Hopkins Cancer Immunology National Cancer Institute program, beyond her many responsibilities of conducting research, working long hours in the clinic, and administrative work, she is a mentor to her fellow faculty members and fellows which she finds to be exceptionally rewarding.
Dr. Brahmer’s medical research to date has centered on immunotherapy of anti-programmed cell death protein 1 antibodies and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies and international phase III studies of immunotherapies in lung cancer, thoracic malignancies drug development and the development of anti-PD-1 antibodies. She is committed to helping develop treatments for mesothelioma and lung cancer through her role as Active Clinical Leader and is also heavily involved in the organization of the Multidisciplinary Thoracic Malignancy.
Dr. Brahmer is a Founding Board Member of the National Lung Cancer Partnership and is actively involved with LUNGevity and Lung Cancer Research Foundation on their respective Medical Advisory Boards. In addition, she is affiliated with a number of other medical associations including the American Association for Cancer Research, the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee, and the Society for Immunotherapy of Cancer.
